(Total Views: 850)
Posted On: 02/22/2022 1:50:36 PM
Post# of 154192
EndPoints News has posted the story. The only new piece they included is this from the company:
The company did not respond to a request for comment on whether it’s taken the video down, and in recent public comments, the company said it’s still developing leronlimab, a CCR5 antagonist, for multiple therapeutic indications.
“We have received the letter from the FDA related to public communications made in 2021 by our former CEO and are reviewing with counsel. We take regulatory oversight very seriously and intend to take appropriate corrective actions to ensure compliance. We will provide a further update in due course,” a company spokesperson said in a statement.
https://endpts.com/fda-slams-former-cytodyn-c...ng-letter/
The company did not respond to a request for comment on whether it’s taken the video down, and in recent public comments, the company said it’s still developing leronlimab, a CCR5 antagonist, for multiple therapeutic indications.
“We have received the letter from the FDA related to public communications made in 2021 by our former CEO and are reviewing with counsel. We take regulatory oversight very seriously and intend to take appropriate corrective actions to ensure compliance. We will provide a further update in due course,” a company spokesperson said in a statement.
https://endpts.com/fda-slams-former-cytodyn-c...ng-letter/
(3)
(0)
